Background:The purpose of the study was to investigatethe active ingredients and potential biochemicalmechanisms of Simiao Wan(SMW)in obesity-associated insulin resistance.Methods:An integrated network pharmacology me...Background:The purpose of the study was to investigatethe active ingredients and potential biochemicalmechanisms of Simiao Wan(SMW)in obesity-associated insulin resistance.Methods:An integrated network pharmacology method to screen the active compoundsand candidate targets,construct the protein-protein-interaction network,and ingredients-targets-pathways network was constructed for topological analysis to identify core targets and main ingredients.To find the possible signaling pathways,enrichment analysis was performed.Further,a model of insulin resistance in HL-7702 cells was established to verify the impact of SMW and the regulatory processes.Results:An overall of 63 active components and 151 candidate targets were obtained,in which flavonoids were the main ingredients.Enrichment analysis indicated that the PI3K-Akt signaling pathway was the potential pathway regulated by SMW in obesity-associated insulin resistance treatment.The result showed that SMW could significantly ameliorate insulin sensitivity,increase glucose synthesis and glucose utilization and reduce intracellular lipids accumulation in hepatocytes.Also,SMW inhibited diacylglycerols accumulation-induced PKCεactivity and decreased its translocation to the membrane.Conclusion:SMW ameliorated obesity-associated insulin resistance through PKCε/IRS-1/PI3K/Akt signaling axis in hepatocytes,providing a new strategy for metabolic disease treatment.展开更多
目的:基于食欲素受体1(OX1R)/磷脂酰肌醇特异性磷酯酶Cβ-1(PLCβ-1)/蛋白激酶Cα(PKCα)/细胞外信号调节激酶1/2(ERK1/2)信号通路探讨安寐丹对失眠大鼠肝脏神经递质及昼夜节律的影响及机制。方法:SPF级SD大鼠60只,随机分为空白组、模...目的:基于食欲素受体1(OX1R)/磷脂酰肌醇特异性磷酯酶Cβ-1(PLCβ-1)/蛋白激酶Cα(PKCα)/细胞外信号调节激酶1/2(ERK1/2)信号通路探讨安寐丹对失眠大鼠肝脏神经递质及昼夜节律的影响及机制。方法:SPF级SD大鼠60只,随机分为空白组、模型组、苏沃雷生组、安寐丹低、中、高剂量组,各10只;除空白组外,其余各组通过腹腔注射对氯苯丙氨酸(PCPA)进行造模,空白组给予等容生理盐水、苏沃雷生组给予苏沃雷生溶液30 mg·kg^(-1)·d^(-1)灌胃、安寐丹低、中、高剂量组分别给予安寐丹水煎液(4.55、9.09、18.18 g·kg^(-1)·d^(-1));观察各组一般情况、体质量和24 h自主活动情况;采用苏木素-伊红(HE)和马松(Masson)染色观察肝脏病理学改变,酶联免疫吸附测定法(ELISA)检测肝脏神经递质γ-氨基丁酸(GABA)、5-羟色胺(5-HT)、肾上腺素(EPI)、去甲肾上腺素(NE)和乙酰胆碱(ACh)的表达,生化检测肝脏谷氨酸(Glu)的表达,实时荧光定量聚合酶链式反应(Real-time PCR)检测肝脏生物钟基因Per1、Per2、Cry1、Cry2、Bmal1、Bmal2的m RNA表达,蛋白免疫印迹法(Western blot)、Real-time PCR检测肝脏OX1R/PLCβ-1/PKCα/ERK1/2信号通路蛋白及m RNA表达。结果:与空白组比较,模型组体质量下降(P<0.05,P<0.01),狂躁、静止节律紊乱(P<0.01),肝脏肌纤维断裂、水肿伴炎性细胞浸润,GABA、5-HT、EPI、NE和ACh含量降低、Glu含量升高(P<0.01),Per1、Per2、Cry1和Cry2 m RNA表达降低(P<0.01),Bmal1和Bmal2 m RNA表达升高(P<0.01),OX1R、PLCβ-1、PKCα、ERK1/2蛋白及m RNA基因表达均增高(P<0.01);与模型组比较,苏沃雷生和安寐丹低、中、高剂量组可增加失眠大鼠体质量(P<0.05,P<0.01),减少狂躁状态、增加其静止时间和频率(P<0.05,P<0.01),并可上调神经递质GABA、5-HT、EPI、NE、ACh和节律基因Per1、Per2、Cry1、Cry2 m RNA表达(P<0.05,P<0.01),抑制Glu及Bmal1、Bmal2、OX1R、PLCβ-1、PKCα、ERK1/2 m RNA和OX1R、PLCβ-1、PKCα、ERK1/2蛋白表达(P<0.05,P<0.01)。结论:安寐丹可通过抑制OX1R/PLCβ-1/PKCα/ERK1/2信号通路调节失眠大鼠肝脏神经递质表达,改善昼夜节律紊乱,且安寐丹高剂量组效果最佳。展开更多
基金supported by the National Natural Science Foundation of China(81903871)Natural Science Foundation of Jiangsu Province(BK20190565)+1 种基金Fundamental Research Funds for the Central Universities(2632021ZD16)Zhenjiang City 2022 Science and Technology Innovation Fund(SH2022084).
文摘Background:The purpose of the study was to investigatethe active ingredients and potential biochemicalmechanisms of Simiao Wan(SMW)in obesity-associated insulin resistance.Methods:An integrated network pharmacology method to screen the active compoundsand candidate targets,construct the protein-protein-interaction network,and ingredients-targets-pathways network was constructed for topological analysis to identify core targets and main ingredients.To find the possible signaling pathways,enrichment analysis was performed.Further,a model of insulin resistance in HL-7702 cells was established to verify the impact of SMW and the regulatory processes.Results:An overall of 63 active components and 151 candidate targets were obtained,in which flavonoids were the main ingredients.Enrichment analysis indicated that the PI3K-Akt signaling pathway was the potential pathway regulated by SMW in obesity-associated insulin resistance treatment.The result showed that SMW could significantly ameliorate insulin sensitivity,increase glucose synthesis and glucose utilization and reduce intracellular lipids accumulation in hepatocytes.Also,SMW inhibited diacylglycerols accumulation-induced PKCεactivity and decreased its translocation to the membrane.Conclusion:SMW ameliorated obesity-associated insulin resistance through PKCε/IRS-1/PI3K/Akt signaling axis in hepatocytes,providing a new strategy for metabolic disease treatment.
文摘目的:基于食欲素受体1(OX1R)/磷脂酰肌醇特异性磷酯酶Cβ-1(PLCβ-1)/蛋白激酶Cα(PKCα)/细胞外信号调节激酶1/2(ERK1/2)信号通路探讨安寐丹对失眠大鼠肝脏神经递质及昼夜节律的影响及机制。方法:SPF级SD大鼠60只,随机分为空白组、模型组、苏沃雷生组、安寐丹低、中、高剂量组,各10只;除空白组外,其余各组通过腹腔注射对氯苯丙氨酸(PCPA)进行造模,空白组给予等容生理盐水、苏沃雷生组给予苏沃雷生溶液30 mg·kg^(-1)·d^(-1)灌胃、安寐丹低、中、高剂量组分别给予安寐丹水煎液(4.55、9.09、18.18 g·kg^(-1)·d^(-1));观察各组一般情况、体质量和24 h自主活动情况;采用苏木素-伊红(HE)和马松(Masson)染色观察肝脏病理学改变,酶联免疫吸附测定法(ELISA)检测肝脏神经递质γ-氨基丁酸(GABA)、5-羟色胺(5-HT)、肾上腺素(EPI)、去甲肾上腺素(NE)和乙酰胆碱(ACh)的表达,生化检测肝脏谷氨酸(Glu)的表达,实时荧光定量聚合酶链式反应(Real-time PCR)检测肝脏生物钟基因Per1、Per2、Cry1、Cry2、Bmal1、Bmal2的m RNA表达,蛋白免疫印迹法(Western blot)、Real-time PCR检测肝脏OX1R/PLCβ-1/PKCα/ERK1/2信号通路蛋白及m RNA表达。结果:与空白组比较,模型组体质量下降(P<0.05,P<0.01),狂躁、静止节律紊乱(P<0.01),肝脏肌纤维断裂、水肿伴炎性细胞浸润,GABA、5-HT、EPI、NE和ACh含量降低、Glu含量升高(P<0.01),Per1、Per2、Cry1和Cry2 m RNA表达降低(P<0.01),Bmal1和Bmal2 m RNA表达升高(P<0.01),OX1R、PLCβ-1、PKCα、ERK1/2蛋白及m RNA基因表达均增高(P<0.01);与模型组比较,苏沃雷生和安寐丹低、中、高剂量组可增加失眠大鼠体质量(P<0.05,P<0.01),减少狂躁状态、增加其静止时间和频率(P<0.05,P<0.01),并可上调神经递质GABA、5-HT、EPI、NE、ACh和节律基因Per1、Per2、Cry1、Cry2 m RNA表达(P<0.05,P<0.01),抑制Glu及Bmal1、Bmal2、OX1R、PLCβ-1、PKCα、ERK1/2 m RNA和OX1R、PLCβ-1、PKCα、ERK1/2蛋白表达(P<0.05,P<0.01)。结论:安寐丹可通过抑制OX1R/PLCβ-1/PKCα/ERK1/2信号通路调节失眠大鼠肝脏神经递质表达,改善昼夜节律紊乱,且安寐丹高剂量组效果最佳。
